Indian drug giant Cipla slashes cancer drug prices

by Penny MacRae

Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".

There are 2.5 million cases of diagnosed in India each year, according to the World Health Organisation, with most patients receiving inadequate treatment as drugs are priced beyond their reach.

"This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients," company chairman Y.K. Hamied said in a statement, which added the price reduction would be only for drugs sold in India.

"Drugs constitute a significant proportion of the overall cost of cancer treatment and a reduction in costs can greatly relieve the burden," he said.

Cipla cut the price of Soranib, a generic version of Bayer's blockbuster drug Nexavar by 76 percent, and will sell it at 6,840 rupees ($130) for a monthly dose, down from 28,000 rupees.

It also said the lung-cancer drug Gefticip, originally produced by , would be priced at 4,250 rupees, down by over half, and it cut by three-quarters the price of brain-cancer drug Temoside, originally made by Schering, to 5,000 rupees.

Cipla, one of India's largest generic drug makers, makes its at its Goa plant, which has been approved by the US Food and Drug Administration.

The family-led company first hit headlines in 2001 when it offered to supply life-saving triple therapy cocktails at prices sharply below those of multinational firms with Hamied saying the move was for "social reasons".

Competition among generic manufacturers in India, known as the "pharmacy to the developing world", has reduced prices from $10,000 per person per year to $150, Medecins Sans Frontieres says.

Cipla, which has been embroiled in a legal dispute with Bayer over its right to produce , said cancer drugs were a small part of its business and the price cuts would not affect revenues.

But analysts said the step could prompt a price war in the 15-billion-rupee Indian drug market -- challenging multinationals which sell costly patented medicine and Indian firms whose generic range is less expensive but not as cheap as Cipla's.

"This market is price-sensitive and when larger players start cutting prices, others will likely follow," Sudarshan Padmanabhan, pharmaceutical analyst at Mumbai investment house Prabhudas Lilladher, told AFP.

Shares in Cipla, whose market value is around $5 billion, rose 2.46 percent to 325.20 rupees on the back of an "outperform" rating by brokerage CLSA, as a falling Indian currency swells foreign earnings and its domestic market grows.

Cipla's step may not only help cancer patients, but "they will reach many more patients, and will also be able to garner greater market share", Anjan Sen, healthcare director at consultancy Deloitte, told the Economic Times.

"It's a smart move."

add to favorites email to friend print save as pdf

Related Stories

Bayer mulls challenge to India cancer drug ruling

Mar 13, 2012

Bayer AG said Tuesday it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.